BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebulized inhaled treprostinil, but it requires a time investment...

Descripción completa

Detalles Bibliográficos
Autores principales: Spikes, Leslie A., Bajwa, Abubakr A., Burger, Charles D., Desai, Sapna V., Eggert, Michael S., El‐Kersh, Karim A., Fisher, Micah R., Johri, Shilpa, Joly, Joanna M., Mehta, Jinesh, Palevsky, Harold I., Ramani, Gautam V., Restrepo‐Jaramillo, Ricardo, Sahay, Sandeep, Shah, Trushil G., Deng, Chunqin, Miceli, Melissa, Smith, Peter, Shapiro, Shelley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063953/
https://www.ncbi.nlm.nih.gov/pubmed/35514770
http://dx.doi.org/10.1002/pul2.12063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063953/
https://www.ncbi.nlm.nih.gov/pubmed/35514770
http://dx.doi.org/10.1002/pul2.12063

Ejemplares similares